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Abstract
Background: Repeated exposure to inhaled allergen can cause airway inflammation, remodeling and dysfunction that
manifests as the symptoms of allergic asthma. We have investigated the role of the cytokine interleukin-13 (IL-13) in the
generation and persistence of airway cellular inflammation, bronchial remodeling and deterioration in airway function in a
model of allergic asthma caused by chronic exposure to the aeroallergen House Dust Mite (HDM).
Methodology/Principal Findings: Mice were exposed to HDM via the intranasal route for 4 consecutive days per week for
up to 8 consecutive weeks. Mice were treated either prophylactically or therapeutically with a potent neutralising anti-IL-13
monoclonal antibody (mAb) administered subcutaneously (s.c.). Airway cellular inflammation was assessed by flow
cytometry, peribronchial collagen deposition by histocytochemistry and airway hyperreactivity (AHR) by invasive
measurement of lung resistance (RL) and dynamic compliance (Cdyn). Both prophylactic and therapeutic treatment with
an anti-IL-13 mAb significantly inhibited (P,0.05) the generation and maintenance of chronic HDM-induced airway cellular
inflammation, peribronchial collagen deposition, epithelial goblet cell upregulation. AHR to inhaled methacholine was
reversed by prophylactic but not therapeutic treatment with anti-IL-13 mAb. Both prophylactic and therapeutic treatment
with anti-IL-13 mAb significantly reversed (P,0.05) the increase in baseline RL and the decrease in baseline Cdyn caused by
chronic exposure to inhaled HDM.
Conclusions/Significance: These data demonstrate that in a model of allergic lung disease driven by chronic exposure to a
clinically relevant aeroallergen, IL-13 plays a significant role in the generation and persistence of airway inflammation,
remodeling and dysfunction.
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Introduction
Chronic exposure of the human airway to inhaled allergen
drives inflammatory processes and remodels airway structure,
resulting in the development of clinical symptoms of asthma. A
mouse disease model driven by chronic exposure of the airway to
whole house dust mite extract (HDM) has been developed to more
accurately understand the dynamic pathophysiological mecha-
nisms linking allergen-induced airway inflammation, structural
changes and dysfunction. HDM is a clinically relevant aeroaller-
gen known to activate the immune system through pattern
recognition receptors [1–3] and proteolytic activity [4]. The HDM
model shares many pathological features with persistent human
asthma, notably eosinophilic airway inflammation, mucus hyper-
secretion, fibrosis of the airway wall and airway hyperreactivity
(AHR) to methacholine [5]. The objective of the work detailed
herein was to determine the role of interleukin-13 (IL-13) in the
generation and persistence of airway pathology caused by chronic
exposure to HDM.
IL-13 is a Th2 cytokine structurally and functionally related to
IL-4 [6]. In contrast to IL-4, IL-13 is unable to polarise T cells or
induce their proliferation [7]. The central role of IL-13 is
considered to be perpetuation of inflammation through the
upregulation of adhesion molecules, metalloproteinases, chemo-
kines and cytokines [8]. In asthmatic patients IL-13 mRNA and
protein is elevated in bronchoalveolar lavage fluid (BAL) following
airway allergen challenge [9–13]. Bronchial expression of IL-13
mRNA positively correlates with the number of eosinophils in
BAL [12] and bronchial biopsy [11]. Furthermore, IL-13 protein
is elevated in sputum from asthmatic patients, and the number of
sub-mucosal cells expressing IL-13 is increased [14,15]. Sub-
mucosal cells expressing IL-13 have been identified as eosinophils
[14] and mast cells [16] although many other cell types are
capable of producing IL-13 in the inflamed airway. Notably, T-
lymphocytes (predominantly, but not exclusively Th2 cells)
represent a major source of IL-13, in addition to macrophages,
basophils, dendritic cells, airway smooth muscle [7,8], and
invariant NKT cells [17].
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airway, or transgenic over-expression of IL-13 in the airway,
is sufficient to induce a phenotype resembling human asthma
pathology, characterised by eosinophilia, airway remodelling,
goblet cell upregulation, mucus hypersecretion and AHR [18–21].
The pharmacology of neutralising anti-IL-13 monoclonal anti-
bodies (mAb) has been investigated in experimental models of
asthma in mice [18,22], sheep [23] and non-human primates
[24,25]. Direct evidence for a role of IL-13 in human asthma has
been reported by Gauvreau et. al. (European Respiratory Society,
Berlin 2008, oral communication) who demonstrated that the
anti-IL-13 mAb IMA-638 significantly inhibited allergen-induced
early and late phase bronchoconstriction in patients with mild
allergic asthma.
The aim of this study was to determine whether IL-13 has a
causative role in the pathogenesis of airway inflammation,
remodelling and dysfunction stimulated by chronic exposure of
mice to inhaled HDM in the absence of adjuvant or peripheral
sensitisation. Furthermore, we sought to determine the importance
of IL-13 during both the development and maintenance of
established airway pathology caused by chronic exposure to
HDM. The aim of the study was met. Using an anti-IL-13
neutralising mAb we demonstrated that IL-13 is important for
both the development and maintenance of airway pathology
caused by pulmonary sensitisation to HDM.
Results
Neutralisation of IL-13 inhibits airway cellular
inflammation
IL-13 protein was upregulated in the lungs after 5 weeks of
exposure to HDM, following the protocol in Figure 1A
(4.1960.38 pg/mg in mice exposed to saline; 7.6260.79 pg/mg
in mice exposed to HDM, p,0.01, Figure 2A). Similarly IL-13
mRNA was significantly elevated in mice exposed to HDM when
compared to mice exposed to saline (6706113 fold, p,0.001,
Figure 2B). Five consecutive weeks of exposure to HDM via the
intra-nasal route stimulated cellular inflammation of the airways,
observed as an elevation in BAL eosinophils, neutrophils and T-
lymphocytes (Figure 3). To determine the role of IL-13 in the
cellular inflammatory response, mice were treated prophylactically
with anti-IL-13 mAb s.c. immediately prior to the first exposure to
intranasal HDM and weekly s.c. thereafter. Prophylactic treatment
with anti-IL-13 mAb (10 mg/kg) significantly inhibited total
CD45
+ leukocyte numbers in BAL fluid by 44% (Figure 3A) and
significantly inhibited the number of siglec-F
+ eosinophils in BAL
by 85% (Figure 3B). Anti-IL-13 treatment significantly reduced
total CD4
+ T-lymphocyte numbers in BAL by 46% (Figure 3C)
and T1ST2
+ Th2 lymphocytes by 60% (Figure 3D). Neutrophil
numbers in BAL were unaffected by treatment with anti-IL-13
mAb (Figure 3E).
Figure 1. Experimental protocols for chronic exposure to house dust mite (HDM). (A) Mice received intranasal HDM on 4 consecutive days
per week for 5 consecutive weeks with concomitant administration of anti-IL-13 mAb, isotype control or vehicle s.c. weekly (prophylactic treatment).
(B) Mice received intranasal HDM on 4 consecutive days per week for 8 consecutive weeks with concomitant administration of anti-IL-13 mAb, isotype
control or vehicle s.c. weekly starting on week 6 (therapeutic treatment). AHR and baseline lung function was assessed as RL and Cdyn in terminally
anaesthetised mice 24 hours after the last HDM instillation on day 32 (A) or day 53 (B). BAL and lungs were removed on day 32 (A) or day 53 (B) for
assessment of airway inflammation and histological analysis. In addition, lungs were taken from an additional group on day 35 for histological
analysis prior to therapeutic treatment (week 5 lungs, B).
doi:10.1371/journal.pone.0013136.g001
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inflammatory response in established disease, mice were exposed to
HDM for 5 consecutive weeks prior to therapeutic administration of
anti-IL-13 mAb (10 mg/kg, s.c., weekly), following the protocol in
Figure 1B. Mice were subsequently exposed to HDM for a further 3
weeks, after which the BAL cellular infiltrate was characterised.
Treatment with anti-IL-13 mAb using this therapeutic dosing regimen
significantly reduced BAL CD45
+ leukocytes by 44% (Figure 3F),
siglec-F
+ eosinophils by 59%; (Figure 3G), CD4
+ T-lymphocytes by
57% (Figure 3H) and T1ST2
+ Th2 lymphocytes by 43% (Figure 3I).
No effects were observed on BAL neutrophil numbers (Figure 3J).
Neutralisation of IL-13 inhibits mucus cell upregulation
Airway mucus hypersecretion associated with goblet cell
hyperplasia and metaplasia is a common feature of asthma that
can be assessed in murine airway disease models by histological
analysis of the airway epithelium. Intranasal administration of
HDM for 5 consecutive weeks provoked a robust increase in the
frequency of goblet cells within the airway epithelia, identified by
AB/PAS staining (Figure 4B). Prophylactic treatment with anti-IL-
13 mAb during the period of exposure to HDM significantly
reduced goblet cell coverage (Figure 4D).
To investigate the role of IL-13 in maintaining elevated goblet
cell number in established disease, mice were exposed to HDM for
5 consecutive weeks prior to commencement of treatment with
anti-IL-13 mAb (10 mg/kg, s.c., weekly) and exposure to HDM
for a further 3 weeks. As shown in Figure 4E, therapeutic
treatment with anti-IL-13 mAb in established disease significantly
reduced epithelial goblet cell coverage when compared to animals
treated with vehicle.
Neutralisation of IL-13 inhibits airway wall remodelling
Administration of HDM to the airways of mice for 5 consecutive
weeks significantly increased the thickness of sub-epithelial
collagen as visualised with Masson’s trichrome stain (Figure 5B).
These data support the observations of Johnson et. al. made in a
similar mouse model using HDM [5]. Prophylactic treatment with
anti-IL-13 mAb significantly inhibited the increase in airway sub-
epithelial collagen thickness stimulated by repeated exposure to
HDM (Figure 5D).
Figure 2. Up regulation of IL-13 in HDM sensitised mice. (A) IL-
13 concentration in lung homogenate after 5 weeks of HDM
sensitisation. (B) IL-13 mRNA expression in lung tissue relative to saline
sensitised mice. Data are shown as mean 6 SEM, n=8 mice per group.
** p,0.01, *** p,0.001 relative to saline group by unpaired t test.
doi:10.1371/journal.pone.0013136.g002
Figure 3. Effect of IL-13 neutralisation on BAL leukocytes. (A–E) Mice were treated prophylactically with anti-IL-13 mAb (10 mg/kg, s.c.,
weekly) administered immediately prior to and throughout HDM exposure. (F–J) Effect of IL-13 neutralisation on established airway inflammation.
Mice were exposed to HDM for 8 consecutive weeks and treated with anti-IL-13 mAb therapeutically (10 mg/kg, s.c., weekly from week 6). Data are
shown as mean 6 SEM, n=8 mice per group. *p,0.05, ** p,0.01, *** p,0.001 relative to HDM group by one-way ANOVA followed by Dunnett’s
post test.
doi:10.1371/journal.pone.0013136.g003
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significantly increased when exposure to HDM was extend-
ed from 5 to 8 consecutive weeks (Figure 5E). Therapeutic
treatment with anti-IL-13 mAb (10 mg/kg, s.c., weekly) starting
from week 6 significantly prevented the additional increase in
peribronchial collagen thickness stimulated by continued
exposure to HDM.
Neutralisation of IL-13 inhibits AHR to methacholine and
improves baseline RL and Cdyn
We have determined the effect of IL-13 neutralisation on lung
function in the HDM model by assessment of RL and Cdyn at
baseline and after methacholine exposure. Five consecutive weeks
of intranasal HDM exposure caused a robust decline in lung
function as shown by elevated baseline RL and reduced baseline
Cdyn. Furthermore, HDM exposure resulted in hyperresponsive-
ness to inhaled methacholine demonstrated by percent change in
RL and Cdyn relative to PBS response (Figure 6). Prophylactic
treatment with anti-IL-13 mAb (10 mg/kg, s.c. weekly) normalised
baseline RL and Cdyn to levels measured in animals exposed to
saline (Figure 6A and 6B). Prophylactic treatment with anti-IL-13
mAb significantly and robustly inhibited AHR to inhaled
methacholine (Figure 6C and 6D).
The therapeutic dosing protocol was employed to determine
the role of IL-13 in maintaining changes in lung function in
established disease (Figure 1B). Therapeutic treatment with anti-
IL-13 mAb from week 6 of exposure to HDM significantly
improved baseline RL and Cdyn measured at week 8 (Figure 6E
and 6F, respectively). However, therapeutic treatment with anti-
IL-13 mAb from week 6 did not inhibit AHR to inhaled
methacholine measured at week 8 (Figure 6G and 6H). In
contrast to the robust effect of prophylactic anti-IL-13 mAb
treatment on AHR to methacholine, therapeutic treatment did
not inhibit AHR despite reversing changes in baseline lung
function.
Figure 4. Effect of IL-13 neutralisation on epithelial goblet cell upregulation. (A–C) Representative photomicrographs of airway sections
stained with AB/PAS (original magnification 6200) from mice exposed for 5 weeks to saline (A) or HDM (B–C) and treated prophylactically with
vehicle (B) or anti-IL-13 mAb (C) (10 mg/kg s.c., weekly) immediately prior to and throughout HDM exposure. (D) Mice were treated prophylactically
with anti-IL-13 mAb (10 mg/kg, s.c., weekly) administered immediately prior to and throughout the 5 consecutive weeks of exposure to HDM. (E)
Effect of anti-IL-13 neutralisation on established goblet cell upregulation. Mice were exposed to HDM for 8 consecutive weeks and treated
therapeutically with anti-IL-13 mAb (10 mg/kg, s.c., weekly from week 6) Week 5 HDM mice represent lung pathology immediately prior to
therapeutic treatment, after 5 weeks of HDM exposure. Data are shown as mean 6 SEM. n=9–10 mice per group. *** p,0.001 relative to HDM group
by one-way ANOVA followed by Dunnett’s post test.
doi:10.1371/journal.pone.0013136.g004
Anti-IL-13 Chronic HDM Model
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In this study we have demonstrated that neutralisation of IL-13
in mice prevents the development and persistence of pathological
and functional changes in the airways caused by repeated
exposure to HDM.
We have employed an experimental protocol using repeated,
prolonged inhaled administration of HDM, in the absence of
experimental adjuvants or peripheral sensitisation, to more
faithfully model the exposure to allergen experienced by asthmatic
patients. Previous studies have shown that chronic exposure of
mice to HDM results in immunological changes and airway
pathology similar to that observed in persistent asthma. Johnson
et.al. report that chronic exposure of mice to inhaled HDM for 5
days per week for up to 7 consecutive weeks stimulated a robust
helper T cell Type 2 (Th2) response, accumulation of inflamma-
tory leukocytes in the lung parenchyma and airways, peribronchial
collagen deposition, epithelial goblet cell upregulation and AHR to
the non-specific inhaled spasmogen methacholine [5]. In the
present study we demonstrate that repeated and continuous
administration of HDM caused accumulation of proinflammatory
effector leukocytes in the airway. Furthermore, in agreement with
the observations of Johnson et. al. [5], we found that chronic
exposure to HDM caused increased collagen deposition in the
bronchial wall, epithelial goblet cell hyperplasia and AHR to
methacholine. Chronic exposure of mice to HDM, without
experimental adjuvant, resulted in significantly increased baseline
lung RL, and decreased Cdyn, measured 24 h after the last HDM
challenge. This is a useful surrogate for the late asthmatic response
and demonstrates how chronic exposure to HDM results in
fundamental changes in airway dynamics.
Prophylactic and therapeutic treatment with a high affinity,
potent, neutralising anti-IL-13 mAb significantly inhibited HDM-
induced airway eosinophilia, goblet cell upregulation and peribron-
chial collagen deposition. In addition anti-IL-13 treatment
significantly inhibited Th2 cell accumulation in the airway. These
data are in agreement with previous reports identifying a central
role for IL-13 in the generation and maintenance of the murine
Figure 5. Effect of IL-13 neutralisation on peribronchial collagen thickness. (A–C) Representative photomicrographs of airway sections
stained with Masson’s trichrome (original magnification6200) from mice exposed for 5 weeks to saline (A) or HDM (B–C) and treated prophylactically
with vehicle (B) or anti-IL-13 mAb (10 mg/kg s.c., weekly) (C) immediately prior to and throughout HDM exposure. (D) Mice were treated
prophylactically with anti-IL-13 mAb (10 mg/kg, s.c., weekly) administered immediately prior to and throughout the 5 consecutive weeks of exposure
to HDM. (E) Effect of anti-IL-13 neutralisation in mice with an established increase in collagen thickness. Mice were exposed to HDM for 8 consecutive
weeks and treated therapeutically with anti-IL-13 mAb (10 mg/kg, s.c., weekly from week 6). Week 5 HDM mice represent lung pathology
immediately prior to therapeutic treatment, after 5 weeks of HDM exposure. Data are shown as mean 6 SEM. n=9–10 mice per group. * p,0.05, ***
p,0.001 relative to HDM group by one-way ANOVA followed by Dunnett’s post test.
doi:10.1371/journal.pone.0013136.g005
Anti-IL-13 Chronic HDM Model
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sensitisation and inhaled exposure to ovalbumin [22,26], aspergillus
[27] or house dust mite [28]. Our data presented herein are the first
demonstrating the importance of IL-13 in maintaining airway
pathology in a disease model established using a clinically relevant
aeroallergenadministeredby the inhaled route only andwithoutthe
use of experimental adjuvants or peripheral sensitisation.
In asthmatic patients AHR to inhaled spasmogens is an
indicator of poor disease control, and is associated with other
relevant outcome measures such as lung function and markers of
lung inflammation [29]. It has been shown clinically in allergic
asthmatic patients that neutralisation of IL-13 improves lung
function following inhaled allergen challenge, but does not prevent
AHR to methacholine (Gauvreau et. al., European Respiratory
Society Berlin 2008, oral communication). A similar lack of effect
on AHR in asthmatic patients was observed using pitrakinra, an
IL-4 receptor antagonist that blocks IL-13 and IL-4 binding to IL-
4Ra [30]. In contrast, neutralisation of IL-13 has been shown to
reduce AHR to inhaled spasmogens in mouse [22] and sheep [23]
models of asthma. We observe that prophylactic treatment with
anti-IL-13 mAb reduced AHR to methacholine, prevented the
increase in baseline airway resistance, RL, and decrease in
dynamic compliance, Cdyn, measured 24 h after allergen chal-
lenge. The effect we observe on baseline RL and Cdyn is consistent
with that obtained in an ovalbumin-driven model in mice using
IL-13R-Fc to neutralise IL-13 [26]. Therapeutic treatment with
anti-IL-13 mAb however reversed the HDM induced changes in
baseline RL and Cdyn without effecting methacholine provoked
AHR. In this study we observe differential effects of anti-IL-13
mAb on AHR to methacholine following prophylactic and
therapeutic treatment. Our data support the existing evidence
that anti-IL-13 mAb are effective in reducing AHR to inhaled
spasmogens in preclinical models, but not AHR to inhaled
spasmogens in asthma patients treated therapeutically. Further-
more our data support the evidence that IL-13 is important for the
late phase decline in lung function in preclinical models and in
asthma patients. There are therapeutics in clinical use, for example
the anti-IgE mAb omalizumab, that do not affect AHR to
methacholine in asthma patients, but do improve the late phase
decline in lung function and reduce the number of disease
exacerbations [31,32]. We are currently conducting studies in a
mouse model of asthma exacerbation to investigate the efficacy of
anti-IL-13 mAb therapy on the decline in lung function and AHR
caused by exposure to HDM with concomitant viral infection.
IL-13 may act directly on airway smooth muscle, causing airway
hyperreactivity to inhaled spasmogens and increase baseline RL.
Studies have shown that IL-13 can directly act on airway smooth
muscle cells to increase contractility [33] and upregulate
leukotriene receptors [34]. IL-13 has been shown to stimulate
autocrine release of IL-5 from ASM, resulting in hyperrespon-
Figure 6. Effect of IL-13 neutralisation on lung function and AHR to inhaled MCh. AHR to MCh was determined as changes in lung
resistance (RL) and dynamic compliance (Cdyn) measured after 5 weeks (A–D) or 8 weeks (E–H) of exposure to HDM. (A–D) Mice were treated
prophylactically with anti-IL-13 mAb (10 mg/kg, s.c., weekly) or isotype control administered immediately prior to and throughout the 5 consecutive
weeks of exposure to HDM. (A, B) Baseline RL and Cdyn were determined prior to MCh exposure. (C, D) Changes in RL and Cdyn in response to MCh
relative to PBS response. (E–H) Mice were exposed to HDM for 8 consecutive weeks and treated therapeutically with anti-IL-13 mAb or isotype control
from week 6 (10 mg/kg, s.c., weekly). (E, F) Baseline RL and Cdyn were determined prior to MCh exposure. (G, H) Changes in RL and Cdyn in response to
MCh relative to PBS response. Data are shown as mean 6 SEM. n=7–8 mice per group. * p,0.05, ** p,0.01, *** p,0.001 relative to HDM group by
one-way ANOVA followed by Dunnett’s post test.
doi:10.1371/journal.pone.0013136.g006
Anti-IL-13 Chronic HDM Model
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addition of effects on ASM contractility, the effect of IL-13 on
baseline RL and Cdyn may be attributable structural changes such
as bronchial fibrosis, goblet cell hyperplasia, and associated mucus
hypersecretion causing airway obstruction. Indeed, mucus plugs
were observed in the airways of some mice following exposure to
HDM (data not shown).
The chronic HDM model of asthma has enabled us to
investigate the effect of anti-IL-13 mAb treatment on both
mechanism and disease-relevant endpoints. The effect of anti-IL-
13 treatment on mechanism-based endpoints, for example
inhibition of airway eosinophilia, are important for understanding
the pharmacology of anti-IL-13 mAb and are findings consistent
with IL-13 stimulating local production of the eosinophil
chemoattractant eotaxin [36]. We suggest that the robust efficacy
of anti-IL-13 mAb on disease-relevant endpoints in this model
indicates where the benefit of anti-IL-13 therapeutics may be seen
in clinical practice. Thus, inhibition of chronic mucus hyperse-
cretion, prevention of continued peribronchial collagen deposition
and decreased airway wall compliance would represent effects of
IL-13 neutralisation with the potential to fundamentally affect
disease progression [37,38].
In conclusion, these data demonstrate that IL-13 neutralisation
reduces airway inflammation, normalises baseline lung function
and reduces AHR to inhaled spasmogen in a mouse model of
asthma driven by a clinically relevant aeroallergen administered
by the inhaled route only, and without the use of experimental
adjuvants. Our data support the proposition that neutralisation of
IL-13 will benefit patients with chronic persistent asthma by
reducing airway inflammation and improving lung function, with
the potential to reduce the number and severity of exacerbations
and the need for corticosteroids.
Materials and Methods
Antibody generation
Murinised anti-mouse IL-13 mAb (CA154_582, mAb A) was
generated by UCB and in vitro activity was characterised as
reported previously [39]. CA154_582 prevents the interaction
between IL-13 and IL-13Ra1 and hence the subsequent
association with IL-4Ra (KD 11pM). In addition this anti-IL-13
mAb blocks IL-13 binding IL-13Ra2.
Mice
Male Balb/c mice (20–25 g) were obtained from Harlan (UK).
All mice were housed in specific pathogen free conditions, in
standard cages and provided with food and water ad libitum. All
experiments were performed in accordance with the UK Animals
(Scientific Procedures) Act 1986.
HDM sensitisation and treatment
Male Balb/c mice were exposed to 25 mg HDM protein (Greer,
USA) in 25 ml sterile saline via the intra-nasal (i.n.) route under
light Isoflurane anaesthesia for 4 consecutive days per week for 5
or 8 weeks. Control mice received 25 ml sterile saline administered
i.n. under light Isoflurane anaesthesia for 4 consecutive days per
week for 5 or 8 weeks. Mice were treated with 10 mg/kg anti-IL-
13 mAb s.c. immediately prior to HDM administration on day 0
or 35 as indicated, and weekly thereafter. HDM sensitised control
mice were dosed with control mouse IgG (10 mg/kg mAb 101.4)
accordingly. Mice were killed 24 hours after the final HDM
exposure. Where therapeutic dosing was employed an additional
HDM sensitised group was killed on day 35 for lung histological
analysis immediately prior to anti-IL-13 treatment (Figure 1).
Measurement of lung IL-13 mRNA and protein
Lung tissue IL-13 mRNA levels were determined in medial lung
lobes relative to 18S expression as previously described in detail
[39]. IL-13 mRNA expression was normalised to that of lungs
from animals exposed to saline. For determination of IL-13
protein in lung tissue, cranial lung lobes were homogenized at
50 mg tissue/ml in HBSS containing ‘complete’ protease inhibitor
cocktail (Roche, UK), prior to centrifugation (208006g, 20 min)
and measurement of IL-13 in supernatant by ELISA (R&D
Systems, UK).
Flow cytometry
BAL sampling was performed post mortem via tracheal cannula
with 360.4 ml PBS (containing 0.4% v/w BSA, 12 mM HEPES
and 500 mM EDTA). BAL cell suspensions were stained with
combinations of anti-mouse CD4, siglec F, Gr-1, CD45 (BD
Biosciences, UK) and T1ST2 (MDbiosciences, USA). BAL
samples were incubated with the antibody cocktail for 20 minutes
on ice. BAL samples were fixed and red cells lysed with BD
FACSlyse (BD Biosciences, UK) prior to centrifugation (4006g,
10 min, RT) and resuspension in PKH26 microbeads (Sigma,
UK) for quantification of events acquired. Total leukocytes were
identified as CD45
+, CD4











hi. Flow cytometric acquisition was
performed using the FACSCanto II system (BD Biosciences, UK)
with offline analysis using Flowjo (version 8.8.4, Tree Star, USA).
Histology
The left lung was excised post mortem and preserved in 10%
formalin (Surgipath, UK), embedded in paraffin and sectioned for
staining with Alcian blue periodic acid Schiff’s stain (AB/PAS) for
mucin or Masson’s Trichrome for collagen. Goblet cell upregula-
tion within the airway epithelia was assessed by measuring the
length of airway basement membrane covered by goblet cells,
expressed as a percentage of total basement membrane length in
each airway. Three bronchioles were selected at random from each
section; one section was analysed per mouse and the mean goblet
cell coverage (%) was calculated for each mouse. Peribronchial
collagen thickness was measured using Image-Pro Plus software
(version 5, Media Cybernetics, USA). Three bronchioles were
selected at random from each section and the mean depth of
collagen from the basement membrane determined from five
measurementsaroundthebronchiole.Onesection wasanalysedper
mouse and the mean collagen depth was calculated for each mouse.
Measurement of Airway Hyperreactivity
AHR was determined by direct measurement of lung resistance
(RL) and dynamic compliance (Cdyn) in anaesthetised, ventilated
mice using FinePointe apparatus (Buxco, USA). Twenty four
hours after HDM instillation mice were terminally anaesthetised
with ketamine (200 mg/kg, i.m.) and pentobarbital (35 mg/kg,
i.p.), tracheotomised and ventilated at 160 breaths/min, tidal
volume 200 ml. After a short period of acclimatisation baseline
measurements of lung function were recorded. Mice were then
exposed to aerosolised PBS and subsequently increasing concen-
trations of aerosolised methacholine via the tracheal cannula (3–
100 mg/ml, Sigma, UK). AHR data is expressed as percent
change from PBS response.
Statistical analysis
Data are representative of two or more studies. Data are
expressed as mean 6 SEM, unless otherwise stated. Statistical
Anti-IL-13 Chronic HDM Model
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variance (ANOVA) with Dunnett’s post test. Differences from
vehicle control are denoted by asterisks whereby * P,0.05, **
P,0.01 and ***P,0.001. Graph generation and statistical
analyses were performed using GraphPad Prism (version 5.01).
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